Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Immucell Corp changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 29 | 26 | −3 |
| Shares | 981.0K | 971.4K | −9.57K (−1.0%) |
| Value | $8.53M | $7.26M | −$1.27M (−14.9%) |
New holders (0)
Institutions that held Immucell Corp at the end of Q3 2022 but not at the end of Q2 2022.
None.
Sold out (3)
Institutions that held Immucell Corp at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Total Clarity Wealth Management, Inc. | 701 | $6.00K |
| Captrust Financial Advisors | 200 | $2.00K |
| Tower Research Capital LLC (TRC) | 153 | $1.00K |